Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
about
Diarrheagenic Escherichia coliEmerging Applications of Bacterial Spores in NanobiotechnologyAdjuvants: Classification, Modus Operandi, and LicensingPlague Vaccine Development: Current Research and Future TrendsCrystal structure of heat-labile enterotoxin from Escherichia coli with increased thermostability introduced by an engineered disulfide bond in the A subunitAttenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strainMutational analysis of the Helicobacter pylori vacuolating toxin amino terminus: identification of amino acids essential for cellular vacuolationMucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.Exploring novel vaccines against Helicobacter pylori: protective and therapeutic immunization.Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvantA recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor.Inhibition of class II major histocompatibility complex antigen processing by Escherichia coli heat-labile enterotoxin requires an enzymatically active A subunitCholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responsesImmunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.Effects of site-directed mutagenesis of Escherichia coli heat-labile enterotoxin on ADP-ribosyltransferase activity and interaction with ADP-ribosylation factors.Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens.Prior immunity to homologous and heterologous Salmonella serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment CIntranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.Coimmunization with complementary glucosyltransferase peptides results in enhanced immunogenicity and protection against dental caries.Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.Vaccine adjuvants: current state and future trends.T-cell-mediated mucosal immunity in the absence of antibody: lessons from Helicobacter pylori infection.A revisit of mucosal IgA immunity and oral tolerance.Vaccination against Helicobacter pylori--an old companion of man.Nasal delivery of antigen with the B subunit of Escherichia coli heat-labile enterotoxin augments antigen-specific T-cell clonal expansion and differentiation.Bacterial spores as vaccine vehicles.Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein.Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines.
P2860
Q24533466-CB504BDA-23FF-4E4F-AE91-1519AC567CABQ24806421-5FBA9FFE-3098-46CD-B8FB-B1EA5D51F491Q26747586-F9D6202A-3D45-4FC1-83AB-A2B673E5A4E9Q28066875-77E4A904-8CD6-4720-AD29-9D043DDD48A7Q30429147-41617E91-F350-495B-AA84-10FE92C2C40BQ33597022-29F62BEA-5650-4403-B701-68DAE56C7C54Q33599389-527B1F2C-015F-470A-9B18-63D69FEBBA32Q33599414-BFE06A60-ACFD-4DB8-95BB-5DAA887B49AEQ33715999-D1F5C6DA-2B20-420B-A824-413E62A049EDQ33727845-FF089C0D-A735-4391-B14B-C0E5ED75812BQ33741147-B423EC3A-350E-4B01-897F-2EB4159D3B47Q33752525-5A8C0129-59CB-4968-82B5-F9D5B242F796Q33757092-4483CEA1-8D4B-4026-ADF8-D9B5863A47B3Q33768109-8C37379C-1D8C-491E-80D0-DBBDED3CE645Q33783470-C651C338-232B-4344-9B1F-FB255D05CE56Q33837275-3546F8D0-F541-431E-8BBE-B9519F503C5EQ33846577-F9695CC8-3D35-4E7B-9EF5-E622489B537BQ33866797-B902724D-B9DE-4E39-BD50-4B5323846DFEQ33955531-BB553325-C517-4B97-B870-47D183CBFCADQ34000007-359F03A9-8BDE-4196-B928-4EC390F96049Q34000623-A1C7FF05-D843-43A7-BD80-07F130173A12Q34001326-96EA9311-C9ED-4F02-95C3-4455F07372C0Q34001509-FB86F003-A3F9-4B1A-9525-331C6D82B9B0Q34001658-A0FB41E5-F78B-4CFF-9D06-852E8B563691Q34002040-6F504966-768F-4D3F-8CD9-A446E3F455F3Q34002470-BD7CA438-CEA4-4A6C-985F-FF716884968FQ34002672-A40085B5-943C-4898-9EA9-9F22990853F4Q34004283-0FDC1A42-375A-4145-8B67-6DD4298B1AC8Q34006385-B9E5ED3B-A85C-484C-AB6A-0086AAEB3D72Q34184890-58FC2B5D-7730-4493-BCBC-694D1D652A93Q34358206-C9B154C8-908E-4E8B-BE73-96235B00A884Q34380115-45F2AE7A-BB9B-4037-824A-17EBB5BA5318Q34419871-BF019C3E-18D9-4874-9F8F-CB1823392599Q34452623-E91DF38B-B35D-4214-AB80-131B323B20B0Q34761512-C0EEEF71-D361-4DDC-BC22-75DEAC2AEF83Q34935167-E2208DB6-7F20-4C52-AC4E-6B5EBDCEC07CQ34975864-ADF73281-F908-4E96-A9C4-14E309FAE37FQ35066293-64B64047-A272-48F9-A3B2-38AFDD86723CQ35171910-CECE36BD-F1B4-4089-B112-47E75A6EB243Q35192203-F2BC884E-C44F-41E8-895F-EA143F344FAA
P2860
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@ast
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@en
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@nl
type
label
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@ast
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@en
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@nl
prefLabel
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@ast
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@en
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@nl
P2093
P2860
P356
P1476
Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants
@en
P2093
Domenghini M
Turcotte C
P2860
P304
P356
10.1073/PNAS.92.5.1644
P407
P577
1995-02-01T00:00:00Z